Clinical Scorecard: Characterization and Standardization Recommendations for Animal Models of Induced Diabetic Neurogenic Bladder Through Systematic Data Analysis
At a Glance
Category
Detail
Condition
Diabetic Neurogenic Bladder (DNB)
Key Mechanisms
Inflammation, oxidative stress, fibrosis, neuroinjury, and cell death.
Target Population
Patients with diabetes mellitus experiencing voiding dysfunction.
Care Setting
Urology and endocrinology.
Key Highlights
DNB affects 40%-60% of patients with diabetes mellitus.
Commonly used animal models include SD rats, Wistar rats, and C57BL/6 mice.
Chemical induction, primarily using streptozotocin (STZ), is the mainstream modeling method.
The typical modeling cycle lasts 8 weeks with a common STZ dose of 60 mg/kg.
Core criteria for successful modeling include blood glucose, urodynamics, and glycated hemoglobin detection.
Guideline-Based Recommendations
Diagnosis
Detection of blood glucose, urodynamics, and glycated hemoglobin (HbA1c) as core criteria.
Management
Pharmaceutical interventions, pelvic floor rehabilitation, neuromodulation techniques, and surgical procedures.
Monitoring & Follow-up
Assessment of voiding dysfunction and renal impairment.
Risks
Potential for severe renal damage if DNB is not properly managed.
